An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line

Laboratory Investigation

Volumn 85, Issue 11, 2005, Pages 1392-1404

  Wang, Yuwei ^a   Xue, Hui ^a   Cutz, Jean Claude ^a,b   Bayani, Jane ^c   Mawji, Nasrin R ^a   Chen, Wilfred G ^d   Goetz, Lester J ^e   Hayward, Simon W ^f   Sadar, Marianne D ^a   Gilks, C Blake ^g   Gout, Peter W ^a   Squire, Jeremy A ^c   Cunha, Gerald R ^h   Wang, Yu Zhuo ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d Carlton Centre   (Trinidad and Tobago)

^e Gulf View Medical ^*  (Trinidad and Tobago)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^g VANCOUVER GENERAL HOSPITAL   (Canada)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Human prostate cancer; Metastatic model; Orthotopic; Subrenal capsule; Xenograft

Indexed keywords

ANDROGEN RECEPTOR; KI 67 ANTIGEN; MITOCHONDRION ANTIBODY; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; CANCER GRAFT; CANCER TRANSPLANTATION; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY METASTASIS; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE; LYMPH NODE METASTASIS; MALE; METASTASIS; MITOCHONDRION; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; SPECTRAL KARYOTYPING; SPLEEN; TUMOR GROWTH; XENOGRAFT;

AGED; ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; LYMPHATIC METASTASIS; MALE; MICE; MICE, SCID; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, HETEROTOPIC;

EID: 27144509295     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700335     Document Type: Article

References (30)

1. Fidler IJ. Critical determinants of metastasis. Semin Cancer Biol 2002;12:89-96.
2. Guseva NV, Taghiyev AF, Rokhlin OW, et al. Death receptor-induced cell death in prostate cancer. J Cell Biochem 2004;91:70-99.
3. Klein KA, Reiter RE, Redula J, et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997;3:402-408.
4. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003;3:453-458.
5. Almholt K, Johnsen M. Stromal cell involvement in cancer. Recent Results Cancer Res 2003;162:31-42.
6. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9:4227-4239.
7. Van Weerden WM, de Ridder CM, Verdaasdonk CL, et al. Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol 1996;149:1055-1062.
8. Lubaroff DM, Cohen MB, Schultz LD, et al. Survival of human prostate carcinoma, benign hyperplastic prostate tissues, and IL-2-activated lymphocytes in scid mice. Prostate 1995;27:32-41.
9. Pretlow TG, Wolman SR, Micale MA, et al. Xenografts of primary human prostatic carcinoma. J Natl Cancer Inst 1993;85:394-398.
10. Wainstein MA, He F, Robinson D, et al. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res 1994;54:6049-6052.
11. Pretlow TG, Delmoro CM, Dilley GG, et al. Transplantation of human prostatic carcinoma into nude mice in matrigel. Cancer Res 1991;51:3814-3817.
12. Stephenson RA, Dinney CP, Gohji K, et al. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst 1992;84:951-957.
13. Wang YZ, Revelo MP, Sudilovsky D, et al. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate 2005;64:149-159.
14. Wang YZ, Hayward SW, Donjacour AA, et al. Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. Cancer Res 2000;60:6008-6017.
15. Wang Y Z, Sudilovsky D, Zhang B, et al. A human prostatic epithelial model of hormonal carcinogenesis. Cancer Res 2001;61:6064-6072.
16. Bayani J, Zielenska M, Marrano P, et al. Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. J Neurosurg 2000;93:437-448.
17. Schrock E, du Manoir S, Veldman T, et al. Multicolor spectral karyotyping of human chromosomes. Science 1996;273:494-497.
18. Pfitzenmaier J, Quinn JE, Odman AM, et al. Characterization of C4-2 prostate cancer bone metastases and their response to castration. J Bone Miner Res 2003;18:1882-1888.
19. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 1998;17:279-284.
20. Radisky DC, Bissell MJ. Cancer. Respect thy neighbor. Science 2004;303:775-777.
21. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-78.
22. Liou LS, Zhou M, Wang Y, et al. A living human tumor bank using an orthotopic xenograft mouse model: feasibility and implications of angiogenesis and proliferation. J Urol 2004;171:208 (abstract).
23. Nemeth JA, Harb JF, Barroso U, et al. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 1999;59:1987-1993.
24. Pan Y, Kytola S, Farnebo F, et al. Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping. Cytogenet Cell Genet 1999;87:225-232.
25. Beheshti B, Karaskova J, Park PC, et al. Identification of a high frequency of chromosomal rearrangements in the centromeric regions of prostate cancer cell lines by sequential giemsa banding and spectral karyotyping. Mol Diagn 2000;5:23-32.
26. Ozen M, Pathak S. Genetic alterations in human prostate cancer: a review of current literature. Anticancer Res 2000;20:1905-1912.
27. Cher ML, MacGrogan D, Bookstein R, et al. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes Cancer 1994;11:153-162.
28. Perinchery G, Sasaki M, Angan A, et al. Deletion of Y-chromosome specific genes in human prostate cancer. J Urol 2000;163:1339-1342.
29. Beheshti B, Park PC, Sweet JM, et al. Evidence of chromosomal instability in prostate cancer determined by spectral karyotyping (SKY) and interphase fish analysis. Neoplasia 2001;3:62-69.
30. Lee CH, Xue H, Sutcliffe M, et al. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol 2005;96:48-55.